AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

In recognition of World Cancer Day 2025, AstraZeneca reaffirms its commitment to advancing early detection, innovative ...

Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

Harvey Jones called on artificial intelligence to help him decide where to invest this year's Stocks and Shares ISA allowance ...

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

In commemoration of World Cancer Day 2025, global biopharmaceutical company AstraZeneca has reinforced its dedication to advancing ...

Vietnam’s pharmaceutical market is expected to have a year of optimism after experiencing a multicoloured gamut in 2024.

Trump's tariffs could derail Europe's 2025 growth, say top Wall Street analysts. Goldman Sachs sees eurozone GDP at 0.7%, ...

Businesses are “abandoning the North Sea” because of Sir Keir Starmer’s decisions, Kemi Badenoch has claimed at PMQs.

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s ...